<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000768</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 183</org_study_id>
    <secondary_id>11158</secondary_id>
    <nct_id>NCT00000768</nct_id>
  </id_info>
  <brief_title>A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients</brief_title>
  <official_title>A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the oral bioavailability of three dose levels of oral ganciclovir given with and&#xD;
      without glutamic acid hydrochloride in patients with cytomegalovirus (CMV) GI disease, and to&#xD;
      compare the bioavailability of these regimens to that of standard intravenous (IV)&#xD;
      ganciclovir.&#xD;
&#xD;
      Long-term ganciclovir maintenance therapy has been recommended for CMV colitis or esophagitis&#xD;
      following induction treatment. Oral ganciclovir is a likely candidate for maintenance because&#xD;
      of its possible therapeutic value and ease of administration, but an optimum dose has not&#xD;
      been determined. Since oral ganciclovir has a low bioavailability and is more soluble in an&#xD;
      acid pH environment, the addition of glutamic acid hydrochloride may enhance gastrointestinal&#xD;
      absorption of this drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-term ganciclovir maintenance therapy has been recommended for CMV colitis or esophagitis&#xD;
      following induction treatment. Oral ganciclovir is a likely candidate for maintenance because&#xD;
      of its possible therapeutic value and ease of administration, but an optimum dose has not&#xD;
      been determined. Since oral ganciclovir has a low bioavailability and is more soluble in an&#xD;
      acid pH environment, the addition of glutamic acid hydrochloride may enhance gastrointestinal&#xD;
      absorption of this drug.&#xD;
&#xD;
      All patients receive an induction regimen of IV ganciclovir administered twice daily for 21&#xD;
      to 42 (Per Amendment 3/4/95) days. A permanent venous catheter is implanted for the induction&#xD;
      therapy. If clinically improved following induction, patients are then randomized to receive&#xD;
      one of three doses of oral ganciclovir, given first without and then with oral glutamic acid&#xD;
      hydrochloride, every 8 hours until they reach a steady state. PER AMENDMENT 3/14/95: After&#xD;
      subjects have reached steady state with oral ganciclovir and glutamic acid hydrochloride then&#xD;
      PK samples will be taken. Subjects will continue the dosing regimen they were assigned to&#xD;
      (glutamic acid hydrochloride will be added if it resulted in at least 33% increased&#xD;
      bioavailability) for up to 12 months or until relapse of CMV GI disease is documented.&#xD;
      Subjects will be followed at monthly intervals for safety evaluation and for evidence of CMV&#xD;
      GI relapse. Subjects who have clinical symptoms of relapse will undergo repeat endoscopy or&#xD;
      colonoscopy to document the relapse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">August 1998</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Colitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamic acid hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Recommended:&#xD;
&#xD;
          -  PCP prophylaxis.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral therapy during induction and pharmacokinetic part of study, provided&#xD;
             patient remains on the same antiretroviral therapy for the duration of the study.&#xD;
&#xD;
          -  Chemotherapy for Kaposi's sarcoma, provided patient is hematologically stable for at&#xD;
             least 30 days prior to study entry.&#xD;
&#xD;
          -  Recombinant human erythropoietin.&#xD;
&#xD;
          -  GM-CSF and G-CSF.&#xD;
&#xD;
          -  Other medications necessary for patient's welfare, at the physician's discretion.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Biopsy-proven cytomegalovirus (CMV) colitis.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  No active AIDS-defining opportunistic infection requiring therapy that is known to&#xD;
             cause nephrotoxicity or myelosuppression.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Kaposi's sarcoma is permitted if patients are hematologically stable for at least 30&#xD;
             days prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Other etiologies for diarrhea identified at study entry.&#xD;
&#xD;
        PER AMENDMENT 3/14/95:&#xD;
&#xD;
          -  For subjects who have diarrhea - no other etiologies for diarrhea identified within 6&#xD;
             weeks of enrollment.&#xD;
&#xD;
          -  Known hypersensitivity to study drugs.&#xD;
&#xD;
          -  CMV retinitis.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acyclovir or probenecid (PER AMENDMENT 3/14/95).&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Biologic response modifiers (other than GM-CSF or G-CSF).&#xD;
&#xD;
          -  Investigational agents, with the exception of treatment IND drugs.&#xD;
&#xD;
          -  Antacids.&#xD;
&#xD;
          -  H2 blockers.&#xD;
&#xD;
          -  Proton pump inhibitors.&#xD;
&#xD;
          -  Foscarnet during induction and pharmacokinetic part of study.&#xD;
&#xD;
          -  Intravenous CMV retinitis maintenance therapy (including ganciclovir) during&#xD;
             pharmacokinetic part of study.&#xD;
&#xD;
          -  Nephrotoxic agents.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 14 days prior to study entry:&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Biologic response modifiers (other than GM-CSF or G-CSF).&#xD;
&#xD;
          -  Investigational agents, with the exception of treatment IND drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacobson M</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Dieterich D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Kotler D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Laine L</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Kumar P</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dieterich DT, Kotler DP, Busch DF, Crumpacker C, Du Mond C, Dearmand B, Buhles W. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis. 1993 Feb;167(2):278-82. doi: 10.1093/infdis/167.2.278.</citation>
    <PMID>8380610</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intestinal Absorption</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Colitis</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Biological Availability</keyword>
  <keyword>Glutamic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

